Pharmacokinetic Interaction of Telmisartan With S-Amlodipine: An Open-Label, Two-Period Crossover Study in Healthy Korean Male Volunteers

Clinical Therapeutics

Volumn 34, Issue 7, 2012, Pages 1625-1635

  Noh, Yook Hwan ^a   Lim, Hyeong Seok ^a,b   Kim, Mi Jo ^a   Kim, Yo Han ^a   Choi, Hee Youn ^a   Sung, Hye Ryoung ^a   Jin, Seok Joon ^a   Lim, Jonglae ^c   Bae, Kyun Seop ^a,b  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Chong Kun Dang Research Institute   (South Korea)

Author keywords

Drug drug interaction; Healthy volunteers; Pharmacokinetics; S amlodipine; Telmisartan

Indexed keywords

AMLODIPINE; TELMISARTAN;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOEQUIVALENCE; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NORTH KOREA; OPEN STUDY; PREVALENCE; SIDE EFFECT; STATISTICAL ANALYSIS; VOMITING;

ADULT; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AREA UNDER CURVE; BENZIMIDAZOLES; BENZOATES; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DRUG INTERACTIONS; FOLLOW-UP STUDIES; HUMANS; MALE; REPUBLIC OF KOREA; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 84863834860     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.05.010     Document Type: Article

References (43)

1. Benndorf R.A., Boger R.H. Pleiotropic effects of telmisartan: still more to come?. J Hypertens 2008, 26:854-856.
2. Battershill A.J., Scott L.J. Telmisartan: a review of its use in the management of hypertension. Drugs 2006, 66:51-83.
3. Karlberg B.E., Lins L.E., Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens 1999, 17:293-302.
4. Neutel J.M., Frishman W.H., Oparil S., et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999, 6:161-166.
5. Dipiro J.T., Talbert R.L., Yee G.C., et al. Pharmacotherapy-A Pathophysiologic Approach 2011, McGraw-Hill, New York, NY. 8th ed.
6. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006, 354:2443-2451.
7. Chazova I.E. Telmisartan (micardis)-an antagonist of angiotensin 2 of type 1 receptors: another antihypertensive drug or something greater?. Ter Arkh 2003, 75:89-91. [in Russian].
8. A summary of the European public assessment report (EPAR) for Pritor Accessed January 14, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000210/WC500042553.pdf.
9. Micardis Briefing document for the Cardiovascular and Renal Drugs Advisory Committee (FDA), Accessed January 14, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM173529.pdf.
10. Haria M., Wagstaff A.J. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995, 50:560-586.
11. Tucker G.T. Chiral switches. Lancet 2000, 355:1085-1087.
12. Goldmann S., Stoltefuss J., Born L. Determination of the absolute configuration of the active amlodipine enantiomer as (-)-S: a correction. J Med Chem 1992, 35:3341-3344.
13. Zhang X.P., Loke K.E., Mital S., et al. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J Cardiovasc Pharmacol 2002, 39:208-214.
14. Rentsch K.M. The importance of stereoselective determination of drugs in the clinical laboratory. J Biochem Biophys Methods 2002, 54:1-9.
15. Luksa J., Josic D., Kremser M., et al. Pharmacokinetic behaviour of R-(+)- and S-(-)-amlodipine after single enantiomer administration. J Chromatogr B Biomed Sci Appl 1997, 703:185-193.
16. Adik-Pathak L. Chiral molecules in hypertension: focus on S-amlodipine. J Assoc Phys India 2004, 52:187-188.
17. Streel B., Laine C., Zimmer C., et al. Enantiomeric determination of amlodipine in human plasma by liquid chromatography coupled to tandem mass spectrometry. J Biochem Biophys Methods 2002, 54:357-368.
18. Cushman W.C., Ford C.E., Cutler J.A., et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4:393-404.
19. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
20. Chrysant S.G. The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies. Am J Cardiovasc Drugs 2010, 10:315-320.
21. da Silva P.M. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan. Clin Drug Invest 2010, 30:625-641.
22. Ishimitsu T., Numabe A., Masuda T., et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009, 32:962-968.
23. Pan F., Chernew M.E., Fendrick A.M. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008, 23:611-614.
24. Guthrie R.M. Review: a single-pill combination of telmisartan plus amlodipine for the treatment of hypertension. Postgrad Med 2011, 123:58-65.
25. Korea good clinical practice (KGCP) guidelines [in Korean] Accessed January 04, 2012. http://clinicaltrials.kfda.go.kr/guide/laws/board_list.jsp?category_seq=12.
26. Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects, 2008 Accessed January 4, 2012. http://www.wma.et/en/30publications/10policies/b3/.
27. Deppe S., Boger R.H., Weiss J., Benndorf R.A. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol 2010, 6:863-871.
28. Kim B.H., Kim J.R., Kim M.G., et al. Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose crossover studies. Clin Ther 2010, 32:193-205.
29. Guidance for Industry, Bioanalytical Method Validation 2003, Korean Food and Drug Administration.
30. Li P., Wang Y., Tang Y., et al. Determination of telmisartan in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2005, 828:126-129.
31. Park J.Y., Kim K.A., Park P.W., et al. Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. Clin Ther 2006, 28:1837-1847.
32. Rowland M., Tozer T.N. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications 2011, Wolters Kluwer/Lippincott Williams & Wilkins, New York, NY. 4th ed.
33. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications 2007, Swedish Pharmaceutical Press, Stockholm, Sweden. 4th ed.
34. Chow S.-C., Liu J.-P. Design and Analysis of Bioavailability and Bioequivalence Studies 2009, CRC Press, Taylor & Francis Group, New York, NY. 3rd ed.
35. Diletti E., Hauschke D., Steinijans V.W. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1992, 30(Suppl 1):S51-S58.
36. Kutner M.H., Nachtsheim C.J., Neter J., Li W. Applied Linear Statistical Models 2005, McGraw-Hill/Irwin, New York, NY. 5th ed.
37. Kroon L.A. Drug interactions and smoking: raising awareness for acute and critical care providers. Crit Care Nurs Clin North Am 2006, 18:53-62. xii.
38. Michel M.C., Bohner H., Koster J., et al. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf 2004, 27:335-344.
39. Endersby C.A., Brown E.G., Perelman M.S. Safety profile of lacidipine: a review of clinical data. J Cardiovasc Pharmacol 1991, 17(Suppl 4):S45-S47.
40. Stangier J., Su C.A. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J Clin Pharmacol 2000, 40:1347-1354.
41. Bolbrinker J., Huber M., Scholze J., Kreutz R. Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. Fundamental Clin Pharmacol 2009, 23:767-774.
42. Philipp T., Smith T.R., Glazer R., et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007, 29:563-580.
43. Littlejohn T.W., Majul C.R., Olvera R., et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009, 11:207-213.